30
MAY
2019
NW Bio To Present Updates On DCVax® Clinical Programs In Industry Theater Presentation At ASCO
Comments : Off
Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial BETHESDA, Md., May 30, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 2, 2019 at 4:15 p.m. CDT (Chicago Time) in the Industry Expert Showcase Theater in the exhibit... Read More